Patient Engagement Janssen partners directly with patients and caregivers as we develop medicines, improve clinical trials, and create educational materials and support programs. See More > Research & Development Our research pipeline is rich with transformational science reflecting our unique approach to ...
Over the past ten years, Janssen has advanced ten new oncology drugs through regulatory approval, including several first-in-class medicines (Fig. 1). Among these are the first fully human bispecific antibody for lung cancer, the first Bruton’s tyrosine kinase (BTK) inhibitor for B cell malig...
“By applying green chemistry principles in the formulation of one of our oncology products,” says Philip Dahlin, Janssen’s Director of Sustainability, “we doubled the process yield and realized significant reductions in raw material use, water use and hazardous waste generation.” In all, ...
M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer and Interim Head, Janssen R&D. “We remain focused on advancing our differentiated pipeline, improving the lives of millions of patients and developing new modalities in areas with the greatest unmet medical need...
M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer and Interim Head, Janssen R&D. “We remain focused on advancing our differentiated pipeline, improving the lives of millions of patients and developing new modalities in areas with the greatest unmet medical need...
La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceuti...
Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen Pharmaceuticals used AWS services, including Amazon SageMaker, to automate and scale its machine learning pipeline, improving model development speed and accuracy.
We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow u...
Awada et al., “The pipeline of new anticancer agents for breast cancer treatment in 2003,” Oncology Hematology, 2003: 48:45-63. Bali et al., “A Combination of Histone Deacetylase Inhibitor LAQ 824 and the FLT-3 Kinase Inhibitor PKC412 is Highly Active Against Human AML Cells with Con...